Bengaluru: BioNTech said on Tuesday its experimental mRNA cancer immunotherapy failed to meet the first main goal of a mid-to-late-stage trial in patients with head and neck cancer.US-listed shares of...
Summary as published by Business Medical Dialogues.
Read the full story
The complete article is on Business Medical Dialogues's website.
Related stories
- Immunology & Vaccines
Pharma Biz
Calluna Pharma completes dosing in phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis
Calluna Pharma AS (Calluna), a clinical─stage biotechnology company pioneering first─in─class antibodies for inflammatory and fibrotic diseases, announced completion of dosing in the phase 2 AURORA study of
Immunology & VaccinesLatestly
WHO Recommends Routine HPV Jabs for Girls As Young as 4
WHO vaccine advisory panel SAGE recommended Tuesday that countries consider routine HPV vaccination for girls as young as four if it improves lagging uptake, as global coverage sits at 33 percent against a 90 percent target. Experts affirmed a single-dose regimen for girls aged 9 to 14 while endorsing expanded catch-up doses to combat cervical cancer globally.
Drugs & TherapeuticsBusiness Medical Dialogues
Generate Biomedicines, Zealand Pharma Join Hands in USD 1.2 Billion AI-Driven Obesity Drug Deal
Bengaluru: Danish obesity-drug developer Zealand Pharma has partnered with US biotechnology company Generate Biomedicines to develop protein-based treatments for obesity and other metabolic diseases...
Immunology & VaccinesMorungexpress
Kiphire workshop seeks to boost HPV vaccination among girls
Kiphire, October 13 (MExN): A district-level coordination workshop to strengthen human papillomavirus (HPV) vaccination and prevent cervical cancer was held at District Hospital, Kiphire, on Monday, with a focus on protecting 14-year-old girls.